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ABSTRACT
Introduction: The intraocular pressure
(IOP)-lowering effect and safety of tafluprost
0.0015%/timolol maleate 0.5% combination
ophthalmic solution (Taf–TFC) were
investigated in a real-world clinical setting.
Methods: A prospective up to 2-year (more
than 1 year) observational study has been
initiated to collect data on the IOP,
conjunctival hyperemia score, corneal staining
score, and adverse events suffered by patients
with glaucoma or ocular hypertension treated at
3 months, and up to 2 years (more than 1 year)
after initiating treatment with Taf–TFC. The
3-month findings are reported here.
Results: Among 439 patients enrolled at 100
institutions in Japan, most had normal tension
glaucoma (45.3%) or primary open angle
glaucoma (36.0%). Adverse drug reaction
(ADR) occurred in 5.01%. The important ADRs
were conjunctival hyperemia (five patients),
blepharitis (four patients), and punctate
keratitis (two patients). Serious adverse
reactions occurred in two patients (three
events). In 410 patients with data both before
and after treatment, baseline mean IOP was
17.5 ± 5.0 mmHg, and it was significantly
decreased after 1, 2, and 3 months (all
P\0.05, paired-t test). IOP was significantly
reduced in patients switched to Taf–TFC from
either prostaglandin or b-blocker monotherapy.
IOP also decreased significantly in patients
switched from a prostaglandin/timolol fixed
combination, but not in patients switched
from concomitant use of a prostaglandin
analog and a b-blocker. The use of Taf–TFC did
not worsen the adherence in most patients.
Conclusion: Taf–TFC significantly reduced the
IOP in patients with glaucoma or ocular
hypertension treated in daily clinical practice
with controllable or recoverable ADRs in short
period. Taf–TFC was effective regardless of
treatment patterns, and particularly, Taf–TFC
significantly reduced IOP in cases in which
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requiring the second line therapy as insufficient
of monotherapy.
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INTRODUCTION
Glaucoma is a chronic disease and still a major
cause of blindness. Most patients with
glaucoma must use ocular hypotensive drugs
continuously throughout their life. However,
since glaucoma is relatively asymptomatic in
the early stage, the low adherence to
ophthalmic solutions for anti-glaucoma was
reported [1]. Poor adherence raises the risk of
the progression of visual field defects [2] and
also the risk of blindness in glaucoma patients
[3].
Nowadays, although prostaglandin analogs
(PGAs) or b-blockers are used in the first-line
therapy because of their potent ocular
hypotensive effects, there are many patients
treated with the concomitant use of two or
more drugs [4]. The concomitant therapy for
glaucoma may cause a decrease in the
adherence due to complicated dosing
regimens, weaken the hypotensive effects with
wash-out effects with a short instillation
interval (less than 5 min), and cause corneal
and/or conjunctival disorders by an increase in
the amount and frequency of preservative
exposure [5]. Therefore, a fixed combination
therapy, when available, should be preferable to
two separate instillations of agents [5].
A fixed combination of tafluprost (0.0015%)
and timolol maleate (0.5%) (Tapcom
combination ophthalmic solution, Santen
Pharmaceutical Co., Ltd., Osaka, Japan:
Taf–TFC) has been developed for the treatment
of glaucoma and ocular hypertension (OH).
Three Japanese phase III clinical trials
conducted in patients with primary
open-angle glaucoma (POAG) or OH have
demonstrated that the intraocular pressure
(IOP)-lowering effect of Taf–TFC is not inferior
to concomitant use of the two active drugs [6]
and is superior to either agent alone [6, 7]. Based
on these findings, Taf–TFC was approved in
Japan in 2014, and it is also marketed in Europe
as a preservative-free solution (Tapticom,
Santen Oy, Finland). However, typically, the
patients in the pivotal clinical studies are
limited in terms of the type and severity of
glaucoma, associated diseases, and concomitant
medications. In addition, treatment was
administered under stringent control. To
obtain more additional information in
real-world setting, a post-marketing study
needs to be performed using various treatment
regimens in a wider variety of patients to
evaluate the efficacy and safety of Taf–TFC in
routine clinical practice. Accordingly, Santen is
currently conducting a long-term observational
study with an up to 2-year (more than 1 year)
follow-up period in a large population of more
than 1000 patients. This report presents the
short-term results obtained with Taf–TFC in
various clinical settings based on analysis of the
data up to 3 months.
METHODS
Study Design
A multicenter, prospective, non-interventional,
observational post-marketing study is being
conducted in accordance with the requirements
of the Japanese regulatory authority (Good
Post-Marketing Study Practice, Ministry of
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Health, Labor and Welfare Ordinance No. 171;
December 20, 2004). The study commenced in
January 2015 and is scheduled to run until
September 2018. Since the protocol was
reviewed and approved by the Japanese
regulatory authority prior to initiation of the
study, approval by the ethics committee at each
participating institution was not required.
Patients and Registration
The inclusion criteria for this study are patients
with glaucoma or OH who had not previously
been treated with Taf–TFC. A central
registration system is used to avoid selection
bias. When a patient meets the inclusion
criteria, the participating physician registers
the patient by facsimile within 2 weeks of
prescribing Taf–TFC. Since the Japanese
regulatory authority does not require informed
consent for post-marketing observational
studies, informed consent is not obtained from
the patients. The observation period has been
set as up to 2 years (more than 1 year) after
starting treatment with Taf–TFC. Data are
collected over two different periods
[0–3 months, and up to 2 years (more than
1 year) after starting treatment], including the
demographic profile (data were collected from
the physician’s report), Taf–TFC regimen,
previous and concomitant drugs, IOP,
objective findings (conjunctival hyperemia
and corneal fluorescein staining), dosing
compliance, and adverse events. Patients are
classified into the following three groups based
on previous and concomitant drugs: ‘‘Naı¨ve,’’
no previous treatment or concomitant drugs;
‘‘Switched,’’ switched to Taf–TFC monotherapy
after treatment with at least one previous drug;
‘‘Concomitant,’’ addition of or switching to
Taf–TFC combined with other anti-glaucoma
medications. A 4-point scale is used to
determine the conjunctival hyperemia and
corneal staining scores: 0, none; 1, mild; 2,
moderate; and 3, severe. If adverse events occur,
the physician evaluates the causal relationship
with Taf–TFC and events for which a causal
relationship to Taf–TFC cannot be excluded are
classified as adverse drug reactions (ADRs). Data
tabulation and analysis were performed using
SAS software (Version 9.2, SAS Institute, Cary,
NC, USA), with results being expressed as the
mean ± standard deviation (SD). The starting
point of treatment with Taf–TFC was used as the
baseline (0 months). The level of statistical
significance was set at 5% (two-sided). The IOP
was compared by the paired t test, and the
scores for objective findings were compared by
Wilcoxon’s signed-rank sum test, with the
P value then being calculated.
RESULTS
Demographic Profile
Data on 439 patients from 100 participating
institutions have been analyzed as of December
2015. The demographic and clinical profile of
these patients is summarized in Table 1.
In this patient cohort, 45.3% were male and
54.7% were female, with a mean age of
67.3 ± 13.1 years (range 21–95 years). The
diagnosis was POAG (untreated
IOP C 21 mmHg) in 36.0%, normal tension
glaucoma (NTG, untreated IOP\21 mmHg) in
45.3%, primary angle-closure glaucoma (PACG)
in 5.0%, OH (untreated IOP C 21 mmHg
without glaucomatous optic neuropathy or
glaucomatous visual field loss) in 8.0%, and
other types of glaucoma in 5.7%. Forty-two
patients discontinued the study before
3 months, including 9 patients (21.4%) in
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whom treatment showed insufficient efficacy (4
patients with POAG, 1 patient each with NTG,
OH and angle-closure glaucoma, and 2 patients
with other glaucoma type), 14 patients (33.3%)
with adverse events (all events were topical
ADRs), 13 patients (31.0%) who withdrew from
study at their own request, and 6 patients
(14.3%) who discontinued for other reasons.
Among the 439 patients, 67 patients (15.3%)
were in the ‘‘Naı¨ve’’ group, 284 patients (64.7%)
were in the ‘‘Switched’’ group, and 88 patients
(20.0%) were in the ‘‘Concomitant’’ group. The
characteristics of each group are summarized in
Fig. 1. The three groups did not show any large
differences of glaucoma type, age, baseline IOP,
and baseline mean deviation (MD) values,
Table 1 Demographic and clinical proﬁle
Total Naı¨ve Switched Concomitant
No. of patients analyzed 439 67 284 88
Sex
Male 199 (45.3) 30 (44.8) 125 (44.0) 44 (50.0)
Female 240 (54.7) 37 (55.2) 159 (56.0) 44 (50.0)
Age (years)
Mean ± SD 67.3 ± 13.1 65.7 ± 14.5 67.2 ± 13.2 68.5 ± 11.7
Minimum–maximum 21.0–95.0 30.0–93.0 21.0–92.0 35.0–95.0
Diagnosis
POAG 158 (36.0) 24 (15.2) 90 (57.0) 44 (27.8)
NTG 199 (45.3) 33 (16.6) 141 (70.9) 25 (12.6)
PACG 22 (5.0) 2 (9.1) 13 (59.1) 7 (31.8)
OH 35 (8.0) 5 (14.3) 28 (80.0) 2 (5.7)
Other types of glaucoma 25 (5.7) 3 (12.0) 12 (48.0) 10 (40.0)
Baseline IOP (mmHg)
Mean ± SD 20.0 ± 6.8 19.1 ± 7.9 19.5 ± 5.6 22.5 ± 8.6
Min–max 8.0–52.0 8.0–52.0 10.0–50.0 8.0–52.0
Ocular complications
Yes 149 (33.9) 32 (47.8) 96 (33.8) 21 (23.9)
No 290 (66.1) 35 (52.2) 188 (66.2) 67 (76.1)
Systemic complications
Yes 196 (51.0) 27 (50.0) 137 (54.2) 32 (41.6)
No 188 (49.0) 27 (50.0) 116 (45.8) 45 (58.4)
Unknown 55 13 31 11
IOP intraocular pressure, NTG normal tension glaucoma, OH ocular hypertension, PACG primary angle-closure glaucoma,
POAG primary open-angle glaucoma, SD standard deviation
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although the ‘‘Naı¨ve’’ group had a higher
proportion of patients aged 30–39 years and
with a baseline IOP of 25 mmHg or over.
Previous medications varied widely in the
‘‘switched’’ group, including PGA monotherapy
(n = 145, 54.5%), PGA and b-blocker (timolol,
carteolol, etc.) concomitant therapy (n = 34,
12.8%), b-blocker (timolol, carteolol, etc.)
monotherapy (n = 28, 10.5%), and
monotherapy with another fixed combination
of PGA and timolol (PGA–TFC) (n = 51,
19.2%).
Adverse Drug Reactions
There were 25 adverse events classified as ADRs
in 22 patients (5.01%) (Table 2). ADRs were
local (affecting the eye) in 20 events and
systemic in 5 events. The major ADRs were
conjunctival hyperemia (5 events), blepharitis
(4 events), and punctate keratitis (2 events). The
serious ADR were recognized in 2 patients (3
events); blood pressure increased, asthenic
conditions (physical deconditioning), and
chest discomfort (one each).
For the case of blood pressure increase,
increased blood pressure was observed after
26 days of administration with Taf–TFC who
was complicated by hypertension (188/
108 mmHg at baseline, 207/138 mmHg at
onset). Increased blood pressure was
unrecovered (226/142 mmHg) at 3 months of
administration with continuing Taf–TFC
administration.
Fig. 1 Background of the three groups. ‘‘Naı¨ve’’ no
previous treatment or concomitant drugs; ‘‘Switched’’
switched to Taf–TFC monotherapy after treatment with
at least one previous drug; ‘‘Concomitant’’ addition
of/switching to Taf–TFC combined with other anti-
glaucoma medications. IOP intraocular pressure, MD
mean deviation, NTG normal tension glaucoma, OH
ocular hypertension, PACG primary angle-closure
glaucoma, POAG primary open-angle glaucoma, Taf–TFC
taﬂuprost 0.0015%/timolol maleate 0.5% combination
ophthalmic solution
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The asthenic conditions (physical
deconditioning) and the chest discomfort were
expressed in the same patient and were both
expressed after 15 days of administration with
Taf–TFC. By the discontinuation of Taf–TFC
drug administration, symptoms were recovered.
The mean hyperemia score was 0.2 ± 0.5
(n = 386) at baseline, 0.2 ± 0.4 (n = 274) at
1 month, 0.2 ± 0.4 (n = 252) at 2 months, and
0.2 ± 0.4 (n = 244) at 3 months. There was no
significant change in the score during the
course of the study. The mean corneal staining
score was 0.2 ± 0.4 (n = 362) at baseline,
0.2 ± 0.4 (n = 256) at 1 month, 0.1 ± 0.4
(n = 234) at 2 months, and 0.1 ± 0.4 (n = 232)
at 3 months. There were no significant changes
of these scores at any time.
IOP-Lowering Effect
Of the 439 patients, IOP data were analyzed in
410 patients in whom the IOP was measured
Table 2 Adverse drug reactions
No. of patients analyzed 439
No. of ADRsa 25
No. of patients with ADRs (%) 22 (5.01)
System organ class Preferred term Events (%)
Eye disorders Abnormal sensation in eye 1 (0.23)
Blepharitis 4 (0.91)
Erythema of eyelid 1 (0.23)
Eye pain 1 (0.23)
Eyelid edema 1 (0.23)
Ocular hyperemia 1 (0.23)
Photopsia 1 (0.23)
Punctate keratitis 2 (0.46)
Vision blurred 1 (0.23)
Growth of eyelashes 1 (0.23)
Conjunctival hyperemia 5 (1.14)
Eye pruritus 1 (0.23)
Cardiac disorders Arrhythmia 1 (0.23)
Palpitations 1 (0.23)
General disorders and administration site conditions Asthenia 1 (0.23)
Chest discomfort 1 (0.23)
Investigations Blood pressure increased 1 (0.23)
a ADR adverse drug reaction (adverse event possibly related to taﬂuprost 0.0015%/timolol maleate 0.5% combination
ophthalmic solution)
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both before and after treatment with Taf–TFC.
The treatment patterns of these 410 patients are
shown in Fig. 2. Their baseline mean IOP was
17.5 ± 5.0 mmHg (n = 410), and mean IOP
changed significantly by -3.0 ± 4.2 at
1 month (n = 282), -3.0 ± 4.3 at 2 months
(n = 266), and -3.2 ± 4.3 mmHg at 3 month
(n = 243) relative to baseline (all P\0.05,
paired-t test) (Table 3; Fig. 3). IOP was
significantly reduced in patients with POAG,
NTG, and OH. The IOP-lowering effect of
Taf–TFC was not influenced by age or sex.
In the ‘‘Naı¨ve’’ group, the mean IOP was
18.6 ± 6.1 mmHg at baseline (n = 59), and it
was significantly reduced at 1, 2, and 3 months
(-4.9 ± 3.3, -4.3 ± 3.0, and -5.1 ± 3.0 mmHg,
respectively, P\0.001, paired t-test, Table 3,
Fig. 3). In the ‘‘Switched’’ group, mean IOP was
17.0 ± 4.2 mmHg at baseline (n = 267), and it
was also significantly reduced at 1, 2, and
3 months (-2.1 ± 2.7, -2.5 ± 3.1, and
-2.4 ± 3.1 mmHg, respectively, P\0.001,
paired t-test, Table 3, Fig. 3). In the
‘‘Concomitant’’ group, mean IOP was
18.2 ± 6.4 mmHg at baseline (n = 84), and it
likewise showed a significant decrease at 1, 2,
and 3 months (-4.5 ± 6.9, -3.9 ± 6.9, and
-4.6 ± 6.9 mmHg respectively, P\0.001,
paired t-test, Table 3, Fig. 3).
In patients switched from PGA monotherapy
to Taf–TFC monotherapy, mean IOP was
17.4 ± 4.0 mmHg at baseline (n = 137), and it
declined significantly at 1, 2, and 3 months
after switching (-2.8 ± 2.1, -3.1 ± 3.2, and
-2.9 ± 3.3 mmHg, respectively, P\0.001,
paired t-test, Table 4, Fig. 4). The IOP
reduction was similar in patients switched
from latanoprost, travoprost or tafluprost to
Taf–TFC monotherapy (Fig. 5). Among patients
switched from PGA monotherapy, IOP
reduction C2 mmHg was defined as
‘‘improved,’’ change of the IOP within
2 mmHg was defined as ‘‘unchanged,’’ and an
increase in IOP by C2 mmHg was defined as
‘‘worse.’’ As a result, 64.3% of patients were
‘‘improved,’’ 31.0% were ‘‘unchanged,’’ and
4.8% were ‘‘worse’’ (Fig. 6). At 3 months,
improvement was noted in 17 patients (70.8%)
switched from latanoprost (n = 24), 24 patients
(60.0%) switched from tafluprost (n = 40), and 5
patients (55.6%) switched from travoprost
(n = 9).
In patients switched from b-blocker (timolol,
carteolol, etc.) monotherapy to Taf–TFC
monotherapy, mean IOP was 16.7 ± 3.7 mmHg
at baseline (n = 25), and it was significantly
Fig. 2 Treatment patterns in 410 patients. ‘‘Naı¨ve’’ no
previous treatment or concomitant drugs; ‘‘Switched’’
switched to Taf–TFC monotherapy after treatment with
at least one previous drug; ‘‘Concomitant’’ addition of/
switching to Taf–TFC combined with other anti-
glaucoma medications. PGA prostaglandin analog, b
b-blocker, PGA–TFC ﬁxed combination of a prostaglandin
analog and timolol, Lat–TFC ﬁxed combination of
latanoprost and timolol, Tra–TFC ﬁxed combination of
travoprost and timolol. Lat–TFC latanoprost/timolol
combination, PGA prostaglandin analogs, Tra–TFC
travoprost/timolol combination
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reduced at 1, 2, and 3 months after switching to
Taf–TFC (-2.5 ± 1.9, -2.6 ± 2.5, and
-4.1 ± 2.1 mmHg, respectively, P\0.05,
paired t-test) (Table 4; Fig. 4).
In patients switched from PGA and b-blocker
(timolol, carteolol, etc.) combined therapy to
Taf–TFC monotherapy, mean IOP was
15.1 ± 2.9 mmHg at baseline (n = 31) and did
not change significantly up to 3 months of
Taf–TFC treatment (paired t-test, Table 4, Fig. 4).
On the other hand, in patients with switched
from other PGA–TFC to Taf–TFC monotherapy,
mean IOP was 18.0 ± 4.9 mmHg at baseline,
and it was significantly reduced at 1, 2, and
3 months after switching to Taf–TFC
(-1.6 ± 2.2, -1.9 ± 2.3, and -1.3 ± 3.1 mmHg,
respectively, P\0.05, paired t-test, Table 4,
Fig. 4). The decrease in IOP with Taf–TFC
monotherapy was similar in patients switched
from the latanoprost/timolol combination
Table 3 IOP stratiﬁed by treatment pattern
Treatment pattern Baseline 1 month 2 months 3 months
All
IOP (mmHg) 17.5 ± 5.0 14.6 ± 4.1 14.5 ± 3.7 14.4 ± 3.6
IOP change (mmHg) – -3.0 ± 4.2 -3.0 ± 4.3 -3.2 ± 4.3
No. of patients 410 282 266 243
P value – \0.001 \0.001 \0.001
Naı¨vea
IOP (mmHg) 18.6 ± 6.1 12.8 ± 3.3 13.8 ± 3.8 13.9 ± 3.2
IOP change (mmHg) -4.9 ± 3.3 -4.3 ± 3.0 -5.1 ± 3.0
No. of patients 59 45 31 30
P value – \0.001 \0.001 \0.001
Switchedb
IOP (mmHg) 17.0 ± 4.2 15.0 ± 4.2 14.4 ± 3.5 14.5 ± 3.7
IOP change (mmHg) – -2.1 ± 2.7 -2.5 ± 3.1 -2.4 ± 3.1
No. of patients 267 181 174 162
P value – \0.001 \0.001 \0.001
Concomitantc
IOP (mmHg) 18.2 ± 6.4 14.6 ± 4.1 14.9 ± 4.1 14.2 ± 3.7
IOP change (mmHg) – -4.5 ± 6.9 -3.9 ± 6.9 -4.6 ± 6.9
No. of patients 84 56 61 51
P value – \0.001 \0.001 \0.001
IOP intraocular pressure, Taf–TFC taﬂuprost 0.0015%/timolol maleate 0.5% combination ophthalmic solution
a ‘‘Naı¨ve,’’ no previous treatment or concomitant drugs
b ‘‘Switched,’’ switched to Taf–TFC monotherapy after treatment with at least one previous drug
c ‘‘Concomitant,’’ addition of/switching to Taf–TFC combined with other anti-glaucoma medications
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(Lat–TFC) or travoprost/timolol combination
(Tra–TFC) drug, but a significant reduction was
not observed in the former patients at 1 month
and in the latter patients at 3 months (Table 4,
Fig. 7). At 3 months, six patients (46.2%)
switched from Lat–TFC (n = 13) and six
patients (50.0%) switched from Tra–TFC
(n = 12) were classified as ‘‘improved’’ (Fig. 8).
Among the 439 patients, 240 patients
instilled Taf–TFC in the morning (before
12:00) and 33 patients used it in the evening
(after 16:00). The baseline mean IOP was
17.2 ± 5.0 mmHg (n = 240) in patients with
morning dosing and 17.3 ± 4.3 mmHg (n = 33)
in patients with evening dosing. With morning
administration of Taf–TFC, IOP was reduced
significantly to 14.2–14.7 mmHg (2.7–3.1
mmHg, 12.8–15.3% decrease), while evening
dosing of Taf–TFC significantly reduced the
IOP to 14.1–14.5 mmHg (2.4–3.9 mmHg,
12.3–20.4% decrease) (Fig. 9).
Adherence
Patient-reported adherence to Taf–TFC therapy
was generally good. As a comparison to prior
medication, we have analyzed data on 316
patients, whose data of both prior medication
and self-reported adherence were available.
Among these 316 patients, only 6 patients
(1.9%) answered that compliance with
medication was worse at 3 months than with
prior medication. The percentage of patients
who answered that compliance was improved
was similar in the ‘‘switched’’ group and the
‘‘concomitant’’ group (20.4% and 19.5%,
respectively). The number of medications
resulted in patient adherence to medication
being improved (Fig. 10).
DISCUSSION
This is the first report on post-marketing
surveillance of Taf–TFC (Tapcom combination
ophthalmic solution) and the first clinical data
for Taf–TFC obtained in the real clinical setting
since its launch. In brief, Taf–TFC reduced IOP
and was well tolerated over a short period.
The majority of patients in this study had
NTG or POAG, accounting for more than 80%
of the subjects combined. The Tajimi Study, an
epidemiological study conducted in Japan by
the Japan Glaucoma Society, found that 72% of
glaucoma patients had NTG [8, 9]. Almost half
of the glaucoma patients in our study had NTG,
also showing that NTG is common among
Japanese glaucoma patients. Besides patients
with NTG, POAG, and OH, our study included
patients with PACG, who have not been
thoroughly investigated in previous clinical
trials. Taf–TFC significantly reduced IOP in
patients with NTG, POAG, and OH, and it also
Fig. 3 IOP changes from baseline in 410 patients. ‘‘Naı¨ve,’’
no previous treatment or concomitant drugs; ‘‘Switched,’’
switched to Taf–TFC monotherapy after treatment with
at least one previous drug; ‘‘Concomitant,’’ addition of/
switching to Taf–TFC combined with other anti-glau-
coma medications. IOP intraocular pressure, Taf–TFC
taﬂuprost 0.0015%/timolol maleate 0.5% combination
ophthalmic solution
Ophthalmol Ther (2016) 5:191–206 199
Table 4 Intraocular pressure stratiﬁed by previous medications
Switched from Baseline 1 month 2 months 3 months
PGA monotherapy
IOP (mmHg) 17.4 ± 4.0 14.4 ± 3.3 14.1 ± 3.0 14.2 ± 3.3
IOP change (mmHg) – -2.8 ± 2.1 -3.1 ± 3.2 -2.9 ± 3.3
No. of patients 137 95 85 84
P value – \0.001 \0.001 \0.001
Latanoprost
IOP (mmHg) 17.4 ± 4.6 14.1 ± 3.1 13.6 ± 2.7 14.1 ± 3.2
IOP change (mmHg) – -3.2 ± 2.4 -3.8 ± 4.3 -3.3 ± 2.7
No. of patients 46 36 26 24
P value – \0.001 \0.001 \0.001
Travoprost
IOP (mmHg) 16.6 ± 3.4 14.8 ± 3.8 13.9 ± 3.6 13.4 ± 3.5
IOP change (mmHg) -2.1 ± 1.6 -1.9 ± 1.6 -2.8 ± 2.8
No. of patients 15 10 9 9
P value – 0.003 0.008 0.016
Taﬂuprost
IOP (mmHg) 16.7 ± 3.8 14.3 ± 3.5 13.6 ± 2.8 13.9 ± 3.5
IOP change (mmHg) -2.7 ± 2.0 -3.1 ± 2.9 -2.5 ± 4.0
No. of patients 60 43 38 40
P value – \0.001 \0.001 \0.001
b-blocker monotherapy
IOP (mmHg) 16.7 ± 3.7 14.7 ± 3.1 13.3 ± 3.0 13.4 ± 3.1
IOP change (mmHg) – -2.5 ± 1.9 -2.6 ± 2.5 -4.1 ± 2.1
No. of patients 25 18 14 17
P value – \0.001 0.002 \0.001
PGA–TFC monotherapy
IOP (mmHg) 18.0 ± 4.9 16.6 ± 5.0 16.4 ± 4.1 17.0 ± 5.0
IOP change (mmHg) – -1.6 ± 2.2 -1.9 ± 2.3 -1.3 ± 3.1
No. of patients 48 28 36 25
P value – \0.001 \0.001 0.04
Lat–TFC
IOP (mmHg) 18.0 ± 5.7 17.4 ± 6.3 16.9 ± 5.0 15.2 ± 4.9
IOP change (mmHg) -1.3 ± 2.5 -1.9 ± 2.6 -1.5 ± 2.5
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tended to reduce IOP in PACG patients. These
results suggest that Taf–TFC is effective for
treating a wide variety of types of glaucoma in
actual clinical practice.
Table 4 continued
Switched from Baseline 1 month 2 months 3 months
No. of patients 23 13 16 13
P value – 0.08 0.01 0.049
Tra–TFC
IOP (mmHg) 18.1 ± 4.1 15.9 ± 3.7 16.0 ± 3.4 18.9 ± 4.7
IOP change (mmHg) -1.8 ± 1.9 -1.9 ± 2.2 -1.1 ± 3.7
No. of patients 25 15 20 12
P value – 0.002 0.001 0.315
Concomitant therapy (PGA, b-blocker)
IOP (mmHg) 15.1 ± 2.9 14.9 ± 3.9 14.5 ± 4.0 14.4 ± 3.6
IOP change (mmHg) – -0.4 ± 2.7 -0.7 ± 3.5 -0.4 ± 2.1
No. of patients 31 22 22 20
P value – 0.458 0.339 0.408
IOP intraocular pressure, Lat–TFC latanoprost/timolol combination, PGA prostaglandin analogs, Tra–TFC
travoprost/timolol combination
Fig. 4 Intraocular pressure changes from baseline in
patients stratiﬁed by switched medications. ‘‘PGA’’ pros-
taglandin analog (latanoprost, travoprost, taﬂuprost,
bimatoprost, or unoprostone); ‘‘b-blocker’’ b-adrenergic
receptor antagonist (timolol or carteolol); ‘‘PGA–TFC’’
ﬁxed combination of a prostaglandin analog and timolol
(latanoprost/timolol or travoprost/timolol); ‘‘concomitant’’
concomitant use of a PGA and a b-blocker. IOP
intraocular pressure, PGA–TFC prostaglandin analogs
and timolol
Fig. 5 Intraocular pressure changes from baseline in
patients switched from prostaglandin analog monotherapy.
IOP intraocular pressure
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In this study, the incidence of ADR was
5.01%, which was lower than in previous
interventional clinical studies [6, 7]. This may
have been related to differences in the extent of
clinical monitoring for adverse events between
an interventional clinical study and daily
clinical practice. In this study, serious ADRs
were observed in two patients. While
uncommon, serious ADRs must be considered
when starting Taf–TFC. The incidence of ADRs
in this study was also lower than that reported
in a post-marketing study of Lat–TFC in Japan
(9.9%) [10]. Since this interim report only
covers a 3-month period, the incidence of
Fig. 6 Efﬁcacy of taﬂuprost/timolol ﬁxed combination in
patient switched from each prostaglandin analog at
3 months. PGA prostaglandin analogs
Fig. 7 Intraocular pressure changes from baseline in
patients switched from a prostaglandin analog/timolol
combination. IOP intraocular pressure, Lat–TFC
latanoprost/timolol combination
Fig. 8 Efﬁcacy of taﬂuprost/timolol ﬁxed combination in
patients switched from each prostaglandin analog/timolol
combination at 3 months. Lat–TFC latanoprost/timolol
combination, PGA–TFC prostaglandin analogs and
timolol, Tra–TFC travoprost/timolol combination
Fig. 9 IOP changes with morning dosing (before noon) or
evening dosing (after 4 pm). IOP intraocular pressure
Fig. 10 Adherence to taﬂuprost/timolol ﬁxed combination
compared with previous medication
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ADRs might increase later, and thus the overall
safety of Taf–TFC should be concluded after this
study have been completed.
In this study, Taf–TFC significantly reduced
the IOP. In the Japanese phase III clinical study,
the efficacy of Taf–TFC was significantly greater
than that of tafluprost monotherapy [6] or
timolol monotherapy [7], and was non-inferior
to that of tafluprost combined with timolol [6].
In this study, the reduction of IOP in patients
switched from PGA monotherapy or b-blocker
monotherapy was similar to that seen in the
phase III studies, confirming superior efficacy of
Taf–TFC over PGA or b-blocker monotherapy in
this real-world study. Previous studies have
shown that some patients exhibit a poor
response to various PGAs [11–13]. Some
reports indicate that poor responders to one
PGA might respond to another PGA [13–15]. In
this study, there were no obvious differences of
the IOP reduction between patients switched
from tafluprost, latanoprost, or travoprost,
indicating that Taf–TFC reduces the IOP in
patients previously treated with any PGA.
Switching to Taf–TFC from another PGA–TFC
(Lat–TFC or Tra–TFC) also significantly reduced
the IOP, but switching to Taf–TFC from
combined PGA and b-blocker therapy did not
significantly reduce and maintain the IOP. In
general, although fixed combinations usually
have clinical equivalence to unfixed
combinations, slight differences in
IOP-lowering efficacy may be seen in some
cases. It is sometimes assumed that the
IOP-lowering effect of fixed combination drugs
is weaker than concomitant use of the
individual active ingredients, because the daily
dose of one active ingredient is decreased. The
difference of the IOP reduction noted in
patients switched from other PGA–TFCs or
concomitant PGA and b-blocker therapy
suggests that the IOP-lowering effect of other
PGA–TFC therapy is weaker than that of
concomitant PGA and b-blocker therapy.
However, once daily Taf–TFC was reported to
show non-inferiority to concomitant use of
tafluprost (once daily) and timolol (twice
daily) [6]. Thus, this study confirmed the
phase III clinical results in the daily clinical
setting. The formulation of Taf–TFC ophthalmic
solution was designed to obtain similar
penetration of timolol into the anterior
chamber as with once daily timolol
gel-forming solution, and this was achieved by
adjusting the pH [16]. Penetration of timolol
into the anterior chamber is pH dependent and
increases with an increase in pH, because
timolol is a basic compound. Indeed,
penetration of timolol into the anterior
chamber was greater after instillation of
Taf–TFC than after a single dose of timolol,
and almost equal to that obtained with timolol
gel-forming solution [16]. This increased
penetration of timolol into the anterior
chamber with Taf–TFC may explain why its
IOP-lowering effect is equal to that of
concomitant PGA and b-blocker therapy,
which may not be the case for all PGA–TFCs.
There was also a significant IOP-lowering effect
when patients were switched from other
PGA–TFCs, with a mean IOP reduction of
about 1.5 mmHg. Clinically, reduction of the
IOP by 1 mmHg is considered to be significant,
because the Early Manifest Glaucoma Trial
(ClinicalTrials.gov identifier, NCT00000132)
revealed an estimated 10% decrease in the risk
of progression for each 1 mm of mercury
reduction in IOP [17].
The question about dosing time of
PGA–TFCs is under debate. Timolol is
recommended to be used in the morning,
because the IOP-lowering effect of timolol
maleate is weaker with dosing at night
compared to that with daytime dosing [18].
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On the other hand, the IOP-lowering effect of
PGAs does not change throughout the day [18]
and most physicians prefer to dose them in the
evening. In addition, the theory on which
dosing time is better for PGA–TFCs is still
controversial. Takmaz reported that while both
morning and evening dosing of Lat–TFC were
effective for lowering the IOP, evening dosing
was more effective than morning dosing in
terms of IOP fluctuation [19]. In contrast, there
were no differences reported between morning
and evening dosing of Lat–TFC [20] and
Tra–TFC [21]. Although no large-scale
comparison on the effect of the dosing time is
available, the results of this study indicate that
both morning and evening dosing for Taf–FDC
can be utilized.
Adherence to glaucoma medication is an
unsolved problem. In principle, treatment of
glaucoma should start with monotherapy using
a first-line drug followed by addition of a
second-line drug or switching to a fixed
combination according to many glaucoma
guidelines (Japan Glaucoma Society, European
Glaucoma Society, etc.). Concomitant use of
two or more ophthalmic solutions may reduce
adherence compared to monotherapy [22], and
the physician must evaluate whether a patient
is likely to adhere to complicated treatment
regimen. Prescription of a fixed combination is
an alternative to two different drugs. In this
study, adherence to Taf–TFC was generally
good, and only six patients (1.9%) reported
that compliance was worse than to previous
medication. Djafari concluded that the use of
fewer medications may improve adherence [22].
In this study, the compliance rate showed the
greatest improvement in patients who
decreased the number of separate medications,
but the improvement in compliance was not
prominent.
Fixed combination drugs are not the first
choice for treating glaucoma except for patients
with a high risk for progression or for patients
with a severe disease. In this study, some
patients started their medication with
Taf–TFC. The treatment pattern of Taf–TFC
was not significantly different for glaucoma
type, age, baseline IOP, and baseline MD
values. However, patients who started with
Taf–TFC tended to have NTG, were
30–39 years old, had a baseline IOP of
25 mmHg or higher, and had an MD value
exceeding -6 dB. This information about
‘‘Naı¨ve’’ patients receiving Taf–TFC
monotherapy may be useful for physicians
when selecting medication.
There were several limitations in this study.
The major limitation of the study is the very
short-term data. Unlike an interventional study,
there was no control group, and specified
examination and drug compliance could not
be controlled in this observational study. Since
we cannot define further the diagnosis of POAG
and NTG, the SD of IOP reduction in this study
was larger than in previous interventional
studies, such as the phase III clinical trial of
Taf–TFC [6]. Despite these limitations, these
data reflect the actual real-world usage of
Taf–TFC, and thus, our findings can serve as a
reference for assessing the future use of Taf–TFC
in clinical practice. Even though this study only
analyzed short-term data up to 3 months, our
results suggest that Taf–TFC is effective for the
treatment of glaucoma in a variety of clinical
settings. Since glaucoma usually requires
chronic treatment, both long-term efficacy
and safety data need to be collected and
analyzed. This up to 2-year observational study
is still ongoing, and the long-term findings will
be presented after the data have been analyzed
at the end of the study period.
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CONCLUSION
Evaluation of the short-term results obtained
during 3 months after starting Taf–TFC
treatment demonstrated that Taf–TFC is
effective for a wide variety of glaucoma types
or OH when administered in actual clinical
practice with controllable or recoverable
adverse reactions. Taf–TFC was effective
regardless of regimens, and particularly,
Taf–TFC significantly reduced IOP in patients
insufficiently controlled on prior monotherapy.
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